The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Bristol-Myers Squibb and AstraZeneca first joined forces to enable the companies to work together in order to research, develop and commercialise select investigational drugs for type 2 diabetes.

Novo Nordisk's Ozempic and Wegovy, among 15 drugs including Pfizer's Ibrance, will face Medicare price negotiations in 2027, ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027.

In a report released on January 15, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

A list of pharmaceutical representatives at the table when the Biden administration negotiated Medicare drug prices reveals ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...